PALB2 Mutation clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
La Jolla, California and other locations